Infinity Group, a manager of cross border China RMB and dollar private equity funds, and local partners have invested a total of RMB220m (approximately US$33m) to establish a life science fund, and an accelerator in Tianjin, China.
The company has launched the Tianjin Israel Life Science Fund in cooperation with local investors including Tianjin Venture Capital Co., Ltd., the Tianjin Economic and Technological Development Zone, Tianjin Mingxuan Investment Co., Ltd and Tianjin Tianying Venture Capital Management Co., Ltd.
The fund is focused on investing in life science companies in China.
Together with Chase Sun Pharmaceuticals and Tianjin VC, Infinity has also co-founded the Tianjin Israel Chase Sun Accelerator, which will focus on developing and commercializing innovative medical devices and pharmaceuticals, from Israel, the U.S. and Europe, for the Chinese market.
Chase Sun is publicly traded on the GEM (Growth Enterprises Market) board in Shenzhen, China, and
Infinity Group was founded by the IDB Group and the China Development Bank. Sectors of focus include: medical device, pharma and healthcare services, information technology, agriculture, materials, as well as water and clean technology and energy.
It operates offices in Beijing, Changzhou, Chengdu, Harbin, Hong Kong, Jining, New York, Ningbo, Shanghai, Shijiazhuang Suzhou, Tel Aviv and Tianjin.